16-30 of 51
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
Sandra Swain, MD
Virginia Kaklamani, MD
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CEAdvancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
MinuteCE®Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
Carey Anders, MD, FASCO
Sarah Sammons, MD
- advertisement
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
MinuteCE®Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
Sarah Sammons, MD
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
MinuteCE®Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
Carey Anders, MD, FASCO
Sarah Sammons, MD
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
MinuteCE®HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
Sarah Sammons, MD
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
MinuteCE®Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
Carey Anders, MD, FASCO
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
MinuteCE®Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Sarah Sammons, MD
Carey Anders, MD, FASCO
Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
MinuteCE®Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
Carey Anders, MD, FASCO
- advertisement
Carey Anders, MD, FASCO
Sarah Sammons, MD
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
CME/CEVirtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Heather McArthur, MD
Margaret Gatti-Mays, MD, MPH
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
